8-K current report · filed Nov 20, 2026

Vanda Pharmaceuticals Inc. (VNDA) 8-K Current Report: November 20, 2026

Item 1.01VNDA overview

Short answer

Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension.

Vanda Pharmaceuticals Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension
  • MSN licensed to launch its generic in Q1 2040, subject to earlier-entry exceptions
  • Settlement preserves near-term HETLIOZ LQ exclusivity while removing litigation uncertainty
  • MSN acknowledged patent validity and agreed not to challenge the licensed patents, subject to exceptions
  • FTC and DOJ review required, with court dismissal and permanent injunction expected

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vanda Pharmaceuticals Inc. 8-K filings

Get the next VNDA 8-K as it lands

Follow VNDA for push alerts, or ask the research agent what this filing means.